Feature / NICE update

NICE published the following guidance during September:

Clinical guidelines

• CG171 Urinary incontinence in women - A costing statement has been produced for this guideline update as it is anticipated many variables could not be estimated by users. There is also considerable variation in local practice in several areas where recommendations have been changed. For example, local circumstances can have an impact on: prescribing patterns for drugs treating overactive bladder; the cost of these drugs; the increase in the use of botulinum toxin A; and the decrease in the use of sacral nerve stimulation.

Technology guidance

• TA 296 Crizotinib for previously treated non- small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene – This technology appraisal is not recommended, so it is not anticipated to have a significant impact on NHS resources.

Diagnostic guidance

• DG 10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management – Mammaprint, Oncotype DX, IHC4 and Mammostrat gene expression profiling and immunohistochemistry tests are designed to improve the targeting of chemotherapy in breast cancer by more accurately identifying patients who will gain the most benefit. The manufacturer of Oncotype DX submitted a proposal to make it easier for the NHS to access the technology. The proposal makes Oncotype DX available at a revised price. The proposal price is commercial in confidence. It is the responsibility of the manufacturer to communicate details of the proposal to the relevant NHS organisations.
  
  The annual cost associated with implementing this recommendation is estimated as £11.5m for the population of England, based on the standard assumptions in the model and the list price of the test (not the revised price from the access proposal)

NICE update was prepared by Stephen Brookfield, senior costing analyst at NICE